Brain+
0.038
DKK
+6.7 %
Less than 1K followers
BRAINP
First North Denmark
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
+6.7%
+14.65%
-18.1%
-13.49%
-3.98%
-45.27%
-96.07%
-
-97.21%
Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.
Read moreMarket cap
36.81M DKK
Turnover
311.83 DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
29/4
2025
Annual report '24
29/5
2025
General meeting '25
28/8
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group
Brain+ A/S: Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools